Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. Report from the OMERACT 11 Myositis Special Interest Group

Helene Alexanderson, Maria Del Grande, Clifton Bingham, Ana-Maria Orbai, Catherine Sarver, Katherine Smith, Ingrid E. Lundberg, Yeong Wook Song, Lisa Christopher-Stine

Research output: Contribution to journalArticle

Abstract

The newly formed Outcome Measures in Rheumatology (OMERACT) Myositis Special Interest Group (SIG) was established to examine patient-reported outcome measures (PROM) in myositis. At OMERACT 11, a literature review of PROM used in the idiopathic inflammatory myopathies (IIM) and other neuromuscular conditions was presented. The group examined in more detail 2 PROM more extensively evaluated in patients with IIM, the Myositis Activities Profile, and the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire, through the OMERACT filter of truth, discrimination, and feasibility. Preliminary results from a qualitative study of patients with myositis regarding their symptoms were discussed that emphasized the range of symptoms experienced: pain, physical tightness/stiffness, fatigue, disease effect on emotional life and relationships, and treatment-related side effects. Following discussion of these results and following additional discussions since OMERACT 11, a research agenda was developed. The next step in evaluating PROM in IIM will require additional focus groups with a spectrum of patients with different myositis disease phenotypes and manifestations across a range of disease activity, and from multiple international settings. The group will initially focus on dermatomyositis and polymyositis in adults. Qualitative analysis will facilitate the identification of commonalities and divergent patient-relevant aspects of disease, insights that are critical given the heterogeneous manifestations of these diseases. Based on these qualitative studies, existing myositis PROM can be examined to more thoroughly assess content validity, and will be important to identify gaps in domain measurement that will be required to develop a preliminary core set of patient-relevant domains for IIM.

Original languageEnglish (US)
Pages (from-to)581-592
Number of pages12
JournalJournal of Rheumatology
Volume41
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Public Opinion
Myositis
Patient Reported Outcome Measures
Dermatomyositis
Patient Preference
Rheumatology
Focus Groups
Arthritis
Fatigue
Outcome Assessment (Health Care)
Phenotype
Pain

Keywords

  • Myositis
  • Outcome and process assessment
  • Patient-reported outcomes

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. Report from the OMERACT 11 Myositis Special Interest Group. / Alexanderson, Helene; Del Grande, Maria; Bingham, Clifton; Orbai, Ana-Maria; Sarver, Catherine; Smith, Katherine; Lundberg, Ingrid E.; Song, Yeong Wook; Christopher-Stine, Lisa.

In: Journal of Rheumatology, Vol. 41, No. 3, 2014, p. 581-592.

Research output: Contribution to journalArticle

@article{26660204091b4d97bfc6b708ffb8d094,
title = "Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. Report from the OMERACT 11 Myositis Special Interest Group",
abstract = "The newly formed Outcome Measures in Rheumatology (OMERACT) Myositis Special Interest Group (SIG) was established to examine patient-reported outcome measures (PROM) in myositis. At OMERACT 11, a literature review of PROM used in the idiopathic inflammatory myopathies (IIM) and other neuromuscular conditions was presented. The group examined in more detail 2 PROM more extensively evaluated in patients with IIM, the Myositis Activities Profile, and the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire, through the OMERACT filter of truth, discrimination, and feasibility. Preliminary results from a qualitative study of patients with myositis regarding their symptoms were discussed that emphasized the range of symptoms experienced: pain, physical tightness/stiffness, fatigue, disease effect on emotional life and relationships, and treatment-related side effects. Following discussion of these results and following additional discussions since OMERACT 11, a research agenda was developed. The next step in evaluating PROM in IIM will require additional focus groups with a spectrum of patients with different myositis disease phenotypes and manifestations across a range of disease activity, and from multiple international settings. The group will initially focus on dermatomyositis and polymyositis in adults. Qualitative analysis will facilitate the identification of commonalities and divergent patient-relevant aspects of disease, insights that are critical given the heterogeneous manifestations of these diseases. Based on these qualitative studies, existing myositis PROM can be examined to more thoroughly assess content validity, and will be important to identify gaps in domain measurement that will be required to develop a preliminary core set of patient-relevant domains for IIM.",
keywords = "Myositis, Outcome and process assessment, Patient-reported outcomes",
author = "Helene Alexanderson and {Del Grande}, Maria and Clifton Bingham and Ana-Maria Orbai and Catherine Sarver and Katherine Smith and Lundberg, {Ingrid E.} and Song, {Yeong Wook} and Lisa Christopher-Stine",
year = "2014",
doi = "10.3899/jrheum.131247",
language = "English (US)",
volume = "41",
pages = "581--592",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "3",

}

TY - JOUR

T1 - Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. Report from the OMERACT 11 Myositis Special Interest Group

AU - Alexanderson, Helene

AU - Del Grande, Maria

AU - Bingham, Clifton

AU - Orbai, Ana-Maria

AU - Sarver, Catherine

AU - Smith, Katherine

AU - Lundberg, Ingrid E.

AU - Song, Yeong Wook

AU - Christopher-Stine, Lisa

PY - 2014

Y1 - 2014

N2 - The newly formed Outcome Measures in Rheumatology (OMERACT) Myositis Special Interest Group (SIG) was established to examine patient-reported outcome measures (PROM) in myositis. At OMERACT 11, a literature review of PROM used in the idiopathic inflammatory myopathies (IIM) and other neuromuscular conditions was presented. The group examined in more detail 2 PROM more extensively evaluated in patients with IIM, the Myositis Activities Profile, and the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire, through the OMERACT filter of truth, discrimination, and feasibility. Preliminary results from a qualitative study of patients with myositis regarding their symptoms were discussed that emphasized the range of symptoms experienced: pain, physical tightness/stiffness, fatigue, disease effect on emotional life and relationships, and treatment-related side effects. Following discussion of these results and following additional discussions since OMERACT 11, a research agenda was developed. The next step in evaluating PROM in IIM will require additional focus groups with a spectrum of patients with different myositis disease phenotypes and manifestations across a range of disease activity, and from multiple international settings. The group will initially focus on dermatomyositis and polymyositis in adults. Qualitative analysis will facilitate the identification of commonalities and divergent patient-relevant aspects of disease, insights that are critical given the heterogeneous manifestations of these diseases. Based on these qualitative studies, existing myositis PROM can be examined to more thoroughly assess content validity, and will be important to identify gaps in domain measurement that will be required to develop a preliminary core set of patient-relevant domains for IIM.

AB - The newly formed Outcome Measures in Rheumatology (OMERACT) Myositis Special Interest Group (SIG) was established to examine patient-reported outcome measures (PROM) in myositis. At OMERACT 11, a literature review of PROM used in the idiopathic inflammatory myopathies (IIM) and other neuromuscular conditions was presented. The group examined in more detail 2 PROM more extensively evaluated in patients with IIM, the Myositis Activities Profile, and the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire, through the OMERACT filter of truth, discrimination, and feasibility. Preliminary results from a qualitative study of patients with myositis regarding their symptoms were discussed that emphasized the range of symptoms experienced: pain, physical tightness/stiffness, fatigue, disease effect on emotional life and relationships, and treatment-related side effects. Following discussion of these results and following additional discussions since OMERACT 11, a research agenda was developed. The next step in evaluating PROM in IIM will require additional focus groups with a spectrum of patients with different myositis disease phenotypes and manifestations across a range of disease activity, and from multiple international settings. The group will initially focus on dermatomyositis and polymyositis in adults. Qualitative analysis will facilitate the identification of commonalities and divergent patient-relevant aspects of disease, insights that are critical given the heterogeneous manifestations of these diseases. Based on these qualitative studies, existing myositis PROM can be examined to more thoroughly assess content validity, and will be important to identify gaps in domain measurement that will be required to develop a preliminary core set of patient-relevant domains for IIM.

KW - Myositis

KW - Outcome and process assessment

KW - Patient-reported outcomes

UR - http://www.scopus.com/inward/record.url?scp=84895423757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895423757&partnerID=8YFLogxK

U2 - 10.3899/jrheum.131247

DO - 10.3899/jrheum.131247

M3 - Article

C2 - 24429182

AN - SCOPUS:84895423757

VL - 41

SP - 581

EP - 592

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 3

ER -